Chondrodysplasias and TGFβ signaling.

Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94

Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature (1991) 11.44

Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol (2005) 11.18

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31

Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science (1998) 7.08

Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet (2004) 6.15

The logic of TGFbeta signaling. FEBS Lett (2006) 5.26

Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol (2007) 4.28

Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93

Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem (2002) 3.92

TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci (2012) 3.49

TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol (2001) 3.22

TGF-beta signaling: a tale of two responses. J Cell Biochem (2007) 2.83

Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet (2011) 2.52

A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem (2009) 2.49

Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet (2012) 2.34

In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet (2003) 2.26

Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem (2003) 2.25

ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet (2004) 2.22

The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature (1998) 2.18

Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet (2000) 2.02

Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell (2000) 2.01

Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev (2005) 2.00

Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem (1995) 1.99

Functional characterization of hypertrophy in chondrogenesis of human mesenchymal stem cells. Arthritis Rheum (2008) 1.83

Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome. Am J Med Genet A (2003) 1.79

ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet (2008) 1.78

Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet (2009) 1.73

Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet (2005) 1.69

Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem (2004) 1.68

Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol (2007) 1.67

Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones. Dev Biol (2004) 1.56

Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet (2011) 1.55

Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors (2011) 1.44

Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2000) 1.43

Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme results in defects in development of the long bones and joints. Dev Biol (2007) 1.42

Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci (2007) 1.37

Smad4 is required for the normal organization of the cartilage growth plate. Dev Biol (2005) 1.29

Acromicric dysplasia. Am J Med Genet (1986) 1.28

Primary murine limb bud mesenchymal cells in long-term culture complete chondrocyte differentiation: TGF-beta delays hypertrophy and PGE2 inhibits terminal differentiation. Bone (2004) 1.28

ADAMTS10 protein interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. J Biol Chem (2011) 1.25

Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. Dev Biol (2009) 1.09

LTBP2 mutations cause Weill-Marchesani and Weill-Marchesani-like syndrome and affect disruptions in the extracellular matrix. Hum Mutat (2012) 1.09

Signaling pathways in human skeletal dysplasias. Annu Rev Genomics Hum Genet (2010) 1.09

TGF-beta3: A potential biological therapy for enhancing chondrogenesis. Expert Opin Biol Ther (2009) 1.07

Geleophysic dwarfism--a "focal" mucopolysaccharidosis? Lancet (1971) 1.06

Microenvironmental regulation by fibrillin-1. PLoS Genet (2012) 1.05

A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene underlies Myhre syndrome. Am J Hum Genet (2012) 1.04

Growth factor impact on articular cartilage subpopulations. Cell Tissue Res (2005) 1.03

Molecular screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of geleophysic dysplasia. J Med Genet (2011) 1.02

Myhre syndrome: new reports, review, and differential diagnosis. J Med Genet (2003) 1.00

Acromicric dysplasia: long term outcome and evidence of autosomal dominant inheritance. J Med Genet (2001) 0.96

Chondrocyte-specific Smad4 gene conditional knockout results in hearing loss and inner ear malformation in mice. Dev Dyn (2009) 0.96

Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol Sci (2014) 0.96

In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet (2012) 0.94

Smad3 activates the Sox9-dependent transcription on chromatin. Int J Biochem Cell Biol (2008) 0.92

Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Mol Cell Biol (2005) 0.84

Myhre syndrome. Clin Genet (2014) 0.80